Dr. Nagourney's Blog

Email-box.png

Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

A New Use for One of the Oldest “New” Drugs - Sorafenib
By Robert A. Nagourney, MD
With the profusion of new targeted agents entering the clinical arena, a report from the American Society of Hematology bears consideration. The trial known as the SORAML trial enrolled 276 patients with newly diagnosed acute myelogenous...
Rare Tumors - Challenges and Triumphs
By Robert A. Nagourney, MD
When I am asked how our EVA-PCD laboratory platform might best be applied, I have several responses. On the one hand, there is...
Melanoma, the Immune System, and Targeted Therapies
By Robert A. Nagourney, MD
For those of you who have been following the recent news coming from the American Society of Clinical Oncology (ASCO)held in...

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.